Eli Lilly and Novo Nordisk’s Obesity Moat Just Got Stronger
The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...
What's Next for Amgen Obesity Drug After Investors Disappointed by Results
Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.
FierceBiotech4d
Amgen's monthly obesity drug matches competition in phase 2, but investors are unimpressed
MariTide, which like Eli Lilly’s Zepound is a dual agonist of the GLP-1 and GIP receptors, demonstrated an average weight ...
Benzinga.com4d
Amgen Reveals Data From Closely Watched Monthly Obesity Drug, With Weight Loss Of Up To 20% At One Year And No Plateau
MariTide is expected to be delivered as a single dose in a handheld, autoinjector device with a monthly or less frequent ...
Amgen stock slips as obesity drug study disappoints Wall Street
Amgen (AMGN) fell sharply during Tuesday's intraday trading following the release of phase two trial results for its monthly ...
Investor's Business Daily on MSN3d
Amgen Dives 5% Despite 'Truly Remarkable' Results For Obesity Treatment
Amgen stock tumbled Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...